Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

512 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
Hazen R, Harvey R, Ferris R, Craig C, Yates P, Griffin P, Miller J, Kaldor I, Ray J, Samano V, Furfine E, Spaltenstein A, Hale M, Tung R, St Clair M, Hanlon M, Boone L. Hazen R, et al. Among authors: tung r. Antimicrob Agents Chemother. 2007 Sep;51(9):3147-54. doi: 10.1128/AAC.00401-07. Epub 2007 Jul 9. Antimicrob Agents Chemother. 2007. PMID: 17620375 Free PMC article.
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.
Miller JF, Andrews CW, Brieger M, Furfine ES, Hale MR, Hanlon MH, Hazen RJ, Kaldor I, McLean EW, Reynolds D, Sammond DM, Spaltenstein A, Tung R, Turner EM, Xu RX, Sherrill RG. Miller JF, et al. Among authors: tung r. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1788-94. doi: 10.1016/j.bmcl.2006.01.035. Epub 2006 Feb 3. Bioorg Med Chem Lett. 2006. PMID: 16458505
Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir.
Furfine ES, Baker CT, Hale MR, Reynolds DJ, Salisbury JA, Searle AD, Studenberg SD, Todd D, Tung RD, Spaltenstein A. Furfine ES, et al. Among authors: tung rd. Antimicrob Agents Chemother. 2004 Mar;48(3):791-8. doi: 10.1128/AAC.48.3.791-798.2004. Antimicrob Agents Chemother. 2004. PMID: 14982766 Free PMC article.
Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease.
Perni RB, Almquist SJ, Byrn RA, Chandorkar G, Chaturvedi PR, Courtney LF, Decker CJ, Dinehart K, Gates CA, Harbeson SL, Heiser A, Kalkeri G, Kolaczkowski E, Lin K, Luong YP, Rao BG, Taylor WP, Thomson JA, Tung RD, Wei Y, Kwong AD, Lin C. Perni RB, et al. Among authors: tung rd. Antimicrob Agents Chemother. 2006 Mar;50(3):899-909. doi: 10.1128/AAC.50.3.899-909.2006. Antimicrob Agents Chemother. 2006. PMID: 16495249 Free PMC article.
Design and synthesis of novel conformationally restricted HIV protease inhibitors.
Salituro FG, Baker CT, Court JJ, Deininger DD, Kim EE, Li B, Novak PM, Rao BG, Pazhanisamy S, Porter MD, Schairer WC, Tung RD. Salituro FG, et al. Among authors: tung rd. Bioorg Med Chem Lett. 1998 Dec 15;8(24):3637-42. doi: 10.1016/s0960-894x(98)00670-2. Bioorg Med Chem Lett. 1998. PMID: 9934485
Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variants.
Perni RB, Britt SD, Court JC, Courtney LF, Deininger DD, Farmer LJ, Gates CA, Harbeson SL, Kim JL, Landro JA, Levin RB, Luong YP, O'Malley ET, Pitlik J, Rao BG, Schairer WC, Thomson JA, Tung RD, Van Drie JH, Wei Y. Perni RB, et al. Bioorg Med Chem Lett. 2003 Nov 17;13(22):4059-63. doi: 10.1016/j.bmcl.2003.08.050. Bioorg Med Chem Lett. 2003. PMID: 14592508
512 results